Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and SAR in NSCLC after PD-1 failure
NCT03158883Phase 1Completed
- Start
- May 2017
- Primary completion
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of avelumab in non-small cell lung cancer (NSCLC) (2 arms). Primary endpoint: Overall Response Rate at 90 days. Started May 2017; status: completed.
02
Drugs
avelumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03158883.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03158883.